CADL
Price
$6.67
Change
-$1.03 (-13.39%)
Updated
Jan 17 closing price
Capitalization
296.43M
67 days until earnings call
KNBIF
Price
$0.07
Change
-$0.01 (-12.50%)
Updated
Jan 17 closing price
Capitalization
9.55M
Ad is loading...

CADL vs KNBIF

Header iconCADL vs KNBIF Comparison
Open Charts CADL vs KNBIFBanner chart's image
Candel Therapeutics
Price$6.67
Change-$1.03 (-13.39%)
Volume$1.91M
Capitalization296.43M
Kane Biotech
Price$0.07
Change-$0.01 (-12.50%)
Volume$13K
Capitalization9.55M
CADL vs KNBIF Comparison Chart
Loading...
CADL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KNBIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CADL vs. KNBIF commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CADL is a Hold and KNBIF is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (CADL: $6.66 vs. KNBIF: $0.07)
Brand notoriety: CADL and KNBIF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CADL: 37% vs. KNBIF: 14%
Market capitalization -- CADL: $296.43M vs. KNBIF: $9.55M
CADL [@Biotechnology] is valued at $296.43M. KNBIF’s [@Biotechnology] market capitalization is $9.55M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CADL’s FA Score shows that 0 FA rating(s) are green whileKNBIF’s FA Score has 0 green FA rating(s).

  • CADL’s FA Score: 0 green, 5 red.
  • KNBIF’s FA Score: 0 green, 5 red.
According to our system of comparison, KNBIF is a better buy in the long-term than CADL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CADL’s TA Score shows that 3 TA indicator(s) are bullish while KNBIF’s TA Score has 4 bullish TA indicator(s).

  • CADL’s TA Score: 3 bullish, 2 bearish.
  • KNBIF’s TA Score: 4 bullish, 2 bearish.
According to our system of comparison, KNBIF is a better buy in the short-term than CADL.

Price Growth

CADL (@Biotechnology) experienced а -18.52% price change this week, while KNBIF (@Biotechnology) price change was -5.95% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

CADL is expected to report earnings on Mar 27, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CADL($296M) has a higher market cap than KNBIF($9.55M). KNBIF YTD gains are higher at: -5.584 vs. CADL (-23.214). KNBIF has higher annual earnings (EBITDA): -3.94M vs. CADL (-48.83M). CADL has more cash in the bank: 16.6M vs. KNBIF (544K). KNBIF has less debt than CADL: KNBIF (2.28M) vs CADL (16M). KNBIF has higher revenues than CADL: KNBIF (2.01M) vs CADL (0).
CADLKNBIFCADL / KNBIF
Capitalization296M9.55M3,099%
EBITDA-48.83M-3.94M1,240%
Gain YTD-23.214-5.584416%
P/E RatioN/A1.87-
Revenue02.01M-
Total Cash16.6M544K3,051%
Total Debt16M2.28M701%
FUNDAMENTALS RATINGS
KNBIF: Fundamental Ratings
KNBIF
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
40
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
56
P/E GROWTH RATING
1..100
65
SEASONALITY SCORE
1..100
75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CADLKNBIF
RSI
ODDS (%)
N/A
Bullish Trend 12 days ago
62%
Stochastic
ODDS (%)
N/A
Bearish Trend 12 days ago
68%
Momentum
ODDS (%)
Bullish Trend 12 days ago
85%
Bullish Trend 12 days ago
72%
MACD
ODDS (%)
Bearish Trend 12 days ago
90%
Bullish Trend 12 days ago
65%
TrendWeek
ODDS (%)
Bullish Trend 12 days ago
86%
Bullish Trend 12 days ago
63%
TrendMonth
ODDS (%)
Bullish Trend 12 days ago
84%
Bearish Trend 12 days ago
60%
Advances
ODDS (%)
Bullish Trend 17 days ago
86%
Bullish Trend 20 days ago
63%
Declines
ODDS (%)
Bearish Trend 13 days ago
90%
N/A
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bullish Trend 12 days ago
84%
Bearish Trend 12 days ago
66%
View a ticker or compare two or three
Ad is loading...
CADL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KNBIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ITEIX10.840.07
+0.65%
VY® T. Rowe Price Equity Income I
RNWGX77.800.35
+0.45%
American Funds New World R6
NDVCX16.940.07
+0.41%
MFS New Discovery Value C
BMSLX14.640.06
+0.41%
MFS Blended Research Mid Cap Eq I
PAXDX8.940.03
+0.34%
Impax Global Sustainable Infras Inv

CADL and

Correlation & Price change

A.I.dvisor indicates that over the last year, CADL has been loosely correlated with CYYNF. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CADL jumps, then CYYNF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CADL
1D Price
Change %
CADL100%
-13.33%
CYYNF - CADL
46%
Loosely correlated
N/A
INKT - CADL
34%
Loosely correlated
+5.77%
MDGL - CADL
33%
Poorly correlated
+7.64%
KRRO - CADL
31%
Poorly correlated
+0.05%
NKTR - CADL
29%
Poorly correlated
+0.03%
More

KNBIF and

Correlation & Price change

A.I.dvisor tells us that KNBIF and CADL have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that KNBIF and CADL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KNBIF
1D Price
Change %
KNBIF100%
-3.07%
CADL - KNBIF
22%
Poorly correlated
-13.33%
LQDA - KNBIF
21%
Poorly correlated
+3.04%
SPHDF - KNBIF
20%
Poorly correlated
N/A
MMIRF - KNBIF
12%
Poorly correlated
N/A
IGXT - KNBIF
7%
Poorly correlated
N/A
More